PT1032697E - Vectores retrovirais de elevada eficiencia que nao possuem quaisquer sequencias codificadoras virais - Google Patents

Vectores retrovirais de elevada eficiencia que nao possuem quaisquer sequencias codificadoras virais

Info

Publication number
PT1032697E
PT1032697E PT99929919T PT99929919T PT1032697E PT 1032697 E PT1032697 E PT 1032697E PT 99929919 T PT99929919 T PT 99929919T PT 99929919 T PT99929919 T PT 99929919T PT 1032697 E PT1032697 E PT 1032697E
Authority
PT
Portugal
Prior art keywords
vectors
retroviral vectors
gene
improved
mlv
Prior art date
Application number
PT99929919T
Other languages
English (en)
Inventor
Kim Sunyoung
Yu Seung Shin
Kim Jong-Mook
Original Assignee
Viromed Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viromed Ltd filed Critical Viromed Ltd
Publication of PT1032697E publication Critical patent/PT1032697E/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/13011—Gammaretrovirus, e.g. murine leukeamia virus
    • C12N2740/13041—Use of virus, viral particle or viral elements as a vector
    • C12N2740/13043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2830/00—Vector systems having a special element relevant for transcription
    • C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/44—Vectors comprising a special translation-regulating system being a specific part of the splice mechanism, e.g. donor, acceptor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
PT99929919T 1998-06-26 1999-06-24 Vectores retrovirais de elevada eficiencia que nao possuem quaisquer sequencias codificadoras virais PT1032697E (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR19980024478 1998-06-26
KR1019990023398A KR20000006334A (ko) 1998-06-26 1999-06-22 바이러스코딩염기서열이전혀없는고효율레트로바이러스벡터

Publications (1)

Publication Number Publication Date
PT1032697E true PT1032697E (pt) 2006-06-30

Family

ID=36320174

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99929919T PT1032697E (pt) 1998-06-26 1999-06-24 Vectores retrovirais de elevada eficiencia que nao possuem quaisquer sequencias codificadoras virais

Country Status (14)

Country Link
US (1) US6451595B1 (pt)
EP (1) EP1032697B1 (pt)
JP (1) JP3864049B2 (pt)
KR (1) KR20000006334A (pt)
CN (1) CN1154744C (pt)
AT (1) ATE324460T1 (pt)
AU (1) AU4655499A (pt)
DE (1) DE69931023T2 (pt)
DK (1) DK1032697T3 (pt)
ES (1) ES2260918T3 (pt)
ID (1) ID24192A (pt)
PT (1) PT1032697E (pt)
RU (1) RU2203321C2 (pt)
WO (1) WO2000000629A1 (pt)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9908788D0 (en) * 1999-04-16 1999-06-09 Univ London Gene expression in eukaryotic cells
GB0027088D0 (en) * 2000-11-06 2000-12-20 Glaxo Group Ltd DNA expression vectors
KR100373821B1 (ko) 2000-09-08 2003-02-26 주식회사 바이로메드 세포에서 유래한 변형된 비코딩 서열을 갖는 개선된고효율 레트로바이러스 벡터
WO2002053191A1 (en) * 2001-01-05 2002-07-11 Viromed Limited Compositions for gene therapy of rheumatoid arthritis including a gene encoding an anti-angiogenic protein or parts thereof
US20060019396A1 (en) * 2004-06-07 2006-01-26 Tissuegene, Inc. Retroviral vectors with enhanced efficiency of transgene expression and safety
GB2450688A (en) * 2005-05-11 2009-01-07 Viragen Inc Ovalbumin promoter constructs for retroviral vectors
US20070092490A1 (en) * 2005-10-20 2007-04-26 Kwan Hee Lee High efficiency sin vector
US8278104B2 (en) * 2005-12-13 2012-10-02 Kyoto University Induced pluripotent stem cells produced with Oct3/4, Klf4 and Sox2
EP4223769A3 (en) * 2005-12-13 2023-11-01 Kyoto University Nuclear reprogramming factor
US8129187B2 (en) * 2005-12-13 2012-03-06 Kyoto University Somatic cell reprogramming by retroviral vectors encoding Oct3/4. Klf4, c-Myc and Sox2
US20090227032A1 (en) * 2005-12-13 2009-09-10 Kyoto University Nuclear reprogramming factor and induced pluripotent stem cells
WO2008044869A1 (en) 2006-10-10 2008-04-17 Viromed Co., Ltd. Expression vectors with improved safety
KR101390967B1 (ko) * 2006-10-10 2014-05-14 주식회사 바이로메드 안전성이 향상된 레트로바이러스 벡터
JP2008307007A (ja) 2007-06-15 2008-12-25 Bayer Schering Pharma Ag 出生後のヒト組織由来未分化幹細胞から誘導したヒト多能性幹細胞
US9213999B2 (en) * 2007-06-15 2015-12-15 Kyoto University Providing iPSCs to a customer
WO2009133971A1 (en) 2008-05-02 2009-11-05 Kyoto University Method of nuclear reprogramming
KR101242114B1 (ko) * 2010-12-30 2013-03-11 성균관대학교산학협력단 초음파 영상 기반의 유전자 전달 기술 및 리포터 유전자를 이용한 생체 내 영상에 의한 형질전환 동물의 선별 방법
WO2012157743A1 (ja) * 2011-05-19 2012-11-22 タカラバイオ株式会社 外来性ｓｄ－ｓａを有するレトロウイルスベクター
KR101427200B1 (ko) 2011-11-24 2014-08-07 주식회사 바이로메드 아데노바이러스 생산 신규 세포주 및 그의 용도
AU2012348558A1 (en) * 2011-12-07 2014-07-10 Glenmark Pharmaceuticals S.A. Expression cassette
CN109385437B (zh) * 2018-06-25 2020-05-26 张凤美 Dna分子、含有该dna分子的载体以及获得的永生化细胞
BR112021007334A2 (pt) 2018-10-19 2021-08-03 Cartexell Inc. anticorpo anti-l1cam ou fragmento de ligação ao antígeno do mesmo, e receptor de antígeno quimérico compreendendo o mesmo
KR20210036742A (ko) 2019-09-26 2021-04-05 주식회사 헬릭스미스 항-c-Met 항체 또는 그의 항원 결합 단편을 포함하는 키메라 항원 수용체, 및 이의 용도
CN113736812A (zh) * 2021-09-06 2021-12-03 武汉翼康基因科技有限公司 一种pcMINI载体及其构建方法与应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1341423C (en) * 1984-10-31 2003-03-04 Paul A. Luciw Recombinant proteins of viruses associated with lymphadenopathy syndrome and/or acquired immune deficiency syndrome
US5906817A (en) * 1993-04-21 1999-05-25 Institut Pasteur Biocompatible implant for the expression and in vivo secretion of a therapeutic substance
FR2716459B1 (fr) * 1994-02-22 1996-05-10 Univ Paris Curie Système hôte-vecteur utilisable en thérapie génique.
AU3258295A (en) * 1994-09-08 1996-03-27 Boehringer Mannheim Gmbh Retroviral vector hybrids and the use thereof for gene transfer
KR100246096B1 (ko) * 1996-09-21 2000-03-15 이선경 유전자 요법을 위한 개선된 레트로바이러스 벡터

Also Published As

Publication number Publication date
DE69931023T2 (de) 2006-11-23
JP2002519037A (ja) 2002-07-02
DK1032697T3 (da) 2006-08-14
CN1154744C (zh) 2004-06-23
US6451595B1 (en) 2002-09-17
AU4655499A (en) 2000-01-17
EP1032697A1 (en) 2000-09-06
EP1032697B1 (en) 2006-04-26
RU2203321C2 (ru) 2003-04-27
DE69931023D1 (de) 2006-06-01
ES2260918T3 (es) 2006-11-01
KR20000006334A (ko) 2000-01-25
CN1277636A (zh) 2000-12-20
ATE324460T1 (de) 2006-05-15
WO2000000629A1 (en) 2000-01-06
ID24192A (id) 2000-06-13
JP3864049B2 (ja) 2006-12-27

Similar Documents

Publication Publication Date Title
PT1032697E (pt) Vectores retrovirais de elevada eficiencia que nao possuem quaisquer sequencias codificadoras virais
JP2022095663A5 (pt)
AR003112A1 (es) Un metodo para controlar la expresion de un gen estructural en una celula, construcciones de adn para uso en dicho metodo y capaz de alterar la expresionde un gen codificante de trombopoyetina, adnasa o interferon beta, molecula de adn aislado, celulas homologamente recombinantes, metodos para producir dichas
DE69435316D1 (de) Verfahren zur herstellung von hohen virustitern und die hocheffiziente transduktion von säugerzellen durch retroviren
CY1107760T1 (el) Κυτταρα φακοϊικου εγκλεισμου
HUP9802217A2 (hu) Rekombináns MVA-vírus és alkalmazása
DK1826215T3 (da) Fremgangsmåde til opnåelse af ekspressionen eller forbedre ekspressionshastigheden af et gen
WO1997007225A3 (en) High efficiency retroviral packaging system
DK1278878T3 (da) Codonoptimerede EIAV-vektorer
JP2016500262A5 (pt)
MX9701684A (es) Expresion del promotor acetohidroxiacido-sintasa de genes introducidos en plantas.
DE69033896D1 (de) Gentechnologische herstellung von impfstoffen gegen aids und andere retrovirale krankheiten
CA2370103A1 (en) Method and means for producing high titer, safe, recombinant lentivirus vectors
WO2021083183A1 (zh) 一种造血干细胞hbb基因修复的方法及产品
ES2116683T3 (es) Gen de la beta-galactosidasa hipertermoestable.
GB2322131A (en) Improved retroviral vectors for gene therapy
DE69432988D1 (de) Für ammonium-transporter kodierende dna-sequenzen und dieser enthaltende, plasmide, bakterien, hefen und pflanzenzellen
ATE91505T1 (de) Herstellung von phenylalanin-ammonialyase.
HUP0101355A2 (hu) Fehérjetermelésre és célba juttatására szolgáló genomi szekvenciák
Fray et al. Identification of unexplained DNA fragments within the T-DNA borders of the Bin 19 plant transformation vector
HUP9902585A2 (hu) Replikálódó molekulák in vivo előállítása
Hurez et al. Gene delivery into primary T cells: overview and characterization of a transgenic model for efficient adenoviral transduction
CN216957522U (zh) 一种加强型高压交联电缆
AR016264A1 (es) Construccion de adn que altera la expresion de un gen endogeno de ifna2 en celulas de mamifero al integrarse al genoma de la celula por medio derecombinacion homologa, celula homologamente recombinante, metodo para alterar la expresion del gen endogeno de ifn2 en una celula de mamifero, uso dedicha
Malik et al. Genetically engineered cures: gene therapy for sickle cell disease